Clinical Trial Update: A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating the effects of canagliflozin on plasma volume in patients with Type 2 diabetes mellitus. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• INVOKANA (CANAGLIFLOZIN)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Diabetes Mellitus, Type 2, Plasma Volume | Phase 1 | Status: COMPLETED